Diphosphonates Concept

subject area of

• 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis  Academic Article
• A 99mTc-Labelled Tetrazine for Bioorthogonal Chemistry. Synthesis and Biodistribution Studies with Small Molecule trans-Cyclooctene Derivatives  Academic Article
• A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial  Academic Article
• A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis.  Academic Article
• A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.  Academic Article
• A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events  Academic Article
• A reappraisal of generic bisphosphonates in osteoporosis  Academic Article
• Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database  Academic Article
• Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data  Academic Article
• Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials  Academic Article
• Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture  Academic Article
• Are bisphosphonates useful in the management of corticosteroid induced osteoporosis in transplant patients?  Academic Article
• Association between timing of zoledronic acid infusion and hip fracture healing  Academic Article
• Atypical Femoral Fractures: A Teaching Perspective  Academic Article
• Atypical femoral fracture  Academic Article
• Bisphosphonate Associated Osteonecrosis of the Jaw  Academic Article
• Bisphosphonate Therapy for Reduced Bone Mineral Density During Treatment of Acute Lymphoblastic Leukemia in Childhood and Adolescence  Academic Article
• Bisphosphonate addition to stable hormone replacement therapy increases bone mineral density in postmenopausal women.  Academic Article
• Bisphosphonate drug holidays: we reap what we sow  Academic Article
• Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada  Academic Article
• Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review  Academic Article
• Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons  Academic Article
• Bisphosphonates Target B Cells to Enhance Humoral Immune Responses  Academic Article
• Bisphosphonates and skeletal morbidity in patients with metastatic cancer.  Academic Article
• Bisphosphonates for osteoporosis in people with cystic fibrosis  Academic Article
• Bisphosphonates for steroid induced osteoporosis  Academic Article
• Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.  Academic Article
• Bone Affinity of a Bisphosphonate-Conjugated Protein in Vivo  Academic Article
• Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care — Cancer Care Ontario Clinical Practice Guideline  Academic Article
• Bone Mineral Metabolism In Pediatric Inflammatory Bowel Disease  Academic Article
• Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors  Academic Article
• Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.  Academic Article
• Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer  Academic Article
• Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ  Academic Article
• Changes in cross-sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (zoledronate)  Academic Article
• Clinical Risk Factors for Recurrent Fracture after Hip Fracture: A Prospective Study  Academic Article
• Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma  Academic Article
• Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis  Academic Article
• Comment on Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis  Academic Article
• Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients  Academic Article
• Corticosteroid-Induced Osteoporosis  Academic Article
• Corticosteroid-Induced Osteoporosis  Academic Article
• Corticosteroid-Induced Osteoporosis  Academic Article
• Current treatment options for osteoporosis.  Academic Article
• Denosumab: mechanism of action and clinical outcomes  Academic Article
• Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus  Academic Article
• Diagnosis and treatment of Paget’s disease of bone  Academic Article
• Discordance between Receptor Status in Primary and Metastatic Breast Cancer: an Exploratory Study of Bone and Bone Marrow Biopsies  Academic Article
• Drug-Related Adverse Events of Osteoporosis Therapy  Academic Article
• Effect of Bisphosphonates on Periprosthetic Bone Mineral Density After Total Joint Arthroplasty  Academic Article
• Effect of Bisphosphonates on Periprosthetic Bone Mineral Density After Total Joint Arthroplasty  Academic Article
• Effect of bisphosphonates on pain and quality of life in patients with bone metastases  Academic Article
• Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer  Academic Article
• Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses  Academic Article
• Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial  Academic Article
• Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study  Academic Article
• Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.  Academic Article
• Endocrine therapy for breast cancer.  Academic Article
• Essence of Evidence-Based Medicine: A Case Report  Academic Article
• Fracture risk and treatment in chronic kidney disease  Academic Article
• Fractures are increased and bisphosphonate use decreased in individuals with insulin-dependent diabetes: a 10 year cohort study  Academic Article
• Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study  Academic Article
• Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study  Academic Article
• Glucocorticoid induced osteoporosis  Academic Article
• Glucocorticoid-induced osteoporosis  Academic Article
• Health-Related Quality of Life and Participation in Osteoporosis Clinical Trials  Academic Article
• Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study  Academic Article
• Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data  Academic Article
• Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging  Academic Article
• Improving care after hip fracture: the fracture? Think osteoporosis (FTOP) program  Academic Article
• In whom and how to prevent glucocorticoid-induced osteoporosis  Academic Article
• Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study  Academic Article
• Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats.  Academic Article
• Influence of bone densitometry results on the treatment of osteoporosis.  Academic Article
• Inhibition of adenosine kinase by phosphonate and bisphosphonate derivatives  Academic Article
• Insufficient evidence to support the use of locally delivered bisphosphonates to improve dental implant outcomes  Academic Article
• Legacy Drug-Prescribing Patterns in Primary Care  Academic Article
• Long-Term Tolerability of the Bisphosphonates in Postmenopausal Osteoporosis  Academic Article
• Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence  Academic Article
• Management of Glucocorticoid-Induced Osteoporosis  Academic Article
• Management of Low Bone Mineral Density in Premenopausal Women  Academic Article
• Management of corticosteroid-induced osteoporosis  Academic Article
• Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer  Academic Article
• Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop  Conference Paper
• Micrometer-Sized Magnesium Whitlockite Crystals in Micropetrosis of Bisphosphonate-Exposed Human Alveolar Bone  Academic Article
• Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study  Academic Article
• Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity  Academic Article
• Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid  Academic Article
• Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture  Academic Article
• Optimal management of metastatic bone disease  Academic Article
• Oral bisphosphonate use in the elderly is not associated with acute kidney injury  Academic Article
• Oral bisphosphonates  Academic Article
• Osteopenia in children with acute lymphoblastic leukemia: A pilot study of amelioration with pamidronate  Academic Article
• Osteoporosis in men: Epidemiology, diagnosis, prevention, and treatment  Academic Article
• Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage  Academic Article
• Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27  Academic Article
• Osteoporosis treatment rate following hip fracture in a community hospital  Academic Article
• Parathyroid hormone for the treatment of osteoporosis: a systematic review  Academic Article
• Patient Adherence to Osteoporosis Medications  Academic Article
• Patient Management, and Time and Health Care Resource Utilization Associated with the Use of Intravenous Bisphosphonates For Patients with Metastatic Bone Disease: A Delphi Study  Academic Article
• Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program  Academic Article
• Pharmacological Treatment of Ankylosing Spondylitis  Academic Article
• Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy  Academic Article
• Postmenopausal Osteoporosis  Academic Article
• Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid  Conference Paper
• Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer  Academic Article
• Preparation and Evaluation of ^99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry  Academic Article
• Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.  Academic Article
• Rational use of oral bisphosphonates for the treatment of osteoporosis  Academic Article
• Relevant clinical end points in biphosphonate trials.  Academic Article
• Reply to T.J. Powles et al  Academic Article
• Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?  Academic Article
• Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)  Academic Article
• Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA  Academic Article
• Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update  Academic Article
• Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis  Academic Article
• Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?  Academic Article
• Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture  Academic Article
• Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial  Academic Article
• The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw  Academic Article
• The Canadian Home Total Parenteral Nutrition (HTPN) Registry  Academic Article
• The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair  Academic Article
• The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function  Conference Paper
• The Role of Bisphosphonates in Malignant Bone Pain: A Review  Academic Article
• The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy  Academic Article
• The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review  Academic Article
• The best use of adjuvant endocrine treatments  Conference Paper
• The gastrointestinal tolerability and safety of oral bisphosphonates  Academic Article
• The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study  Academic Article
• The osteoporosis care gap in Canada  Academic Article
• The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study  Academic Article
• The role of bisphosphonates in early- and advanced-stage breast cancer: have we finally optimized care?  Academic Article
• The treatment of glucocorticoid-induced osteoporosis  Academic Article
• The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials.  Academic Article
• Time and Labor Costs Associated With Administration of Intravenous Bisphosphonates for Breast or Prostate Cancer Patients With Metastatic Bone Disease: A Time and Motion Study  Academic Article
• Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease  Academic Article
• Treating osteoporosis: economic aspects of bisphosphonate therapy  Academic Article
• Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 3: Prevention of osteoporosis and CV effects of estrogens and antiestrogens.  Conference Paper
• Tumor-bone interactions in skeletal metastasis.  Academic Article
• Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline  Academic Article
• Use of Osteobiologics in the Management of Osteoporotic Fractures  Academic Article
• What are the beliefs, attitudes and practices of front-line staff in long-term care (LTC) facilities related to osteoporosis awareness, management and fracture prevention?  Academic Article
• Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis  Academic Article
• Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials  Academic Article
• Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity  Academic Article
• Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.  Academic Article
• Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program  Academic Article
• Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion  Academic Article
• Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial  Academic Article
• Zoledronic acid use in cancer patients  Academic Article
• [Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].  Academic Article